- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
South San Francisco Today
By the People, for the People
Allogene Therapeutics to Announce Interim Futility Analysis Data from ALPHA3 Trial
The biotech company will share results from its pivotal Phase 2 study of a CAR T-cell therapy for first-line large B-cell lymphoma.
Apr. 13, 2026 at 3:56am
Got story updates? Submit your updates here. ›
Allogene's 'off-the-shelf' CAR T-cell therapy aims to make this promising cancer treatment more widely accessible.South San Francisco TodayAllogene Therapeutics, a clinical-stage biotech company focused on allogeneic CAR T-cell therapies, announced it will host a conference call and webcast on Monday, April 13, 2026 to review the interim futility analysis from its pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line consolidation large B-cell lymphoma (LBCL).
Why it matters
Allogene's cema-cel is an 'off-the-shelf' CAR T-cell therapy that could provide a more scalable and reliable treatment option for LBCL patients compared to autologous CAR T therapies. The ALPHA3 trial results will be an important milestone in the development of this potential new therapy.
The details
The ALPHA3 trial is a randomized, pivotal Phase 2 study evaluating cema-cel as a first-line consolidation treatment for LBCL. The interim futility analysis will assess whether the study should continue based on pre-defined criteria. Allogene will host a live conference call and webcast at 5:30am PT / 8:30am ET on April 13, 2026 to review the data.
- Allogene will host the conference call and webcast on Monday, April 13, 2026.
- The interim futility analysis from the ALPHA3 trial will be reviewed during the event.
The players
Allogene Therapeutics
A clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, headquartered in South San Francisco.
cemacabtagene ansegedleucel (cema-cel)
Allogene's investigational 'off-the-shelf' CAR T-cell therapy being evaluated in the ALPHA3 trial for first-line consolidation treatment of large B-cell lymphoma.
What’s next
The results of the interim futility analysis will determine whether the ALPHA3 trial continues as planned.
The takeaway
The ALPHA3 trial results will be a key milestone in Allogene's efforts to develop a scalable, 'off-the-shelf' CAR T-cell therapy option for first-line large B-cell lymphoma patients, potentially expanding access to this promising treatment approach.
